TY - JOUR
T1 - Ezetimibe reduces urinary albumin excretion in hypercholesterolaemic type 2 diabetes patients with microalbuminuria
AU - Nakamura, T.
AU - Sato, E.
AU - Amaha, M.
AU - Kawagoe, Y.
AU - Maeda, S.
AU - Inoue, H.
AU - Yamagishi, S. I.
PY - 2012/4
Y1 - 2012/4
N2 - Objective: This study investigated the effects of ezetimibe, an inhibitor of intestinal cholesterol absorption, on early phase diabetic nephropathy. Methods: A total of 32 hypercholesterolaemic type 2 diabetes patients with microalbuminuria, defined as a urinary albumin excretion (UAE) ≥ 30 but < 300 mg/g creatinine, were enrolled. Various clinical and laboratory parameters were determined at baseline and after 6 months of treatment with 10 mg/day ezetimibe. Results: Ezetimibe treatment significantly decreased glycated haemoglobin (HbA1c), low-density lipoprotein-cholesterol (LDL-C), triglycerides and UAE, and significantly increased high-density lipoprotein-cholesterol and albumin. It also decreased the serum level of monocyte chemoattractant protein-1 (MCP-1), but this difference was not statistically significant. Univariate analyses showed a correlation between UAE and body mass index, systolic and diastolic blood pressures, HbA1c, LDL-C, estimated glomerular filtration rate (inverse), creatinine and MCP-1. Since these parameters may be closely correlated with each other, multiple stepwise regression analysis was performed and demonstrated that HbA1c and MCP-1 were independent determinants of UAE. Conclusions: Ezetimibe may be a promising therapeutic strategy for improving albumin excretion, partly through its anti-inflammatory properties, and for reducing LDL-C in hypercholesterolaemic type 2 diabetes patients with microalbuminuria.
AB - Objective: This study investigated the effects of ezetimibe, an inhibitor of intestinal cholesterol absorption, on early phase diabetic nephropathy. Methods: A total of 32 hypercholesterolaemic type 2 diabetes patients with microalbuminuria, defined as a urinary albumin excretion (UAE) ≥ 30 but < 300 mg/g creatinine, were enrolled. Various clinical and laboratory parameters were determined at baseline and after 6 months of treatment with 10 mg/day ezetimibe. Results: Ezetimibe treatment significantly decreased glycated haemoglobin (HbA1c), low-density lipoprotein-cholesterol (LDL-C), triglycerides and UAE, and significantly increased high-density lipoprotein-cholesterol and albumin. It also decreased the serum level of monocyte chemoattractant protein-1 (MCP-1), but this difference was not statistically significant. Univariate analyses showed a correlation between UAE and body mass index, systolic and diastolic blood pressures, HbA1c, LDL-C, estimated glomerular filtration rate (inverse), creatinine and MCP-1. Since these parameters may be closely correlated with each other, multiple stepwise regression analysis was performed and demonstrated that HbA1c and MCP-1 were independent determinants of UAE. Conclusions: Ezetimibe may be a promising therapeutic strategy for improving albumin excretion, partly through its anti-inflammatory properties, and for reducing LDL-C in hypercholesterolaemic type 2 diabetes patients with microalbuminuria.
KW - Albuminuria
KW - Diabetic nephropathy
KW - Ezetimibe
KW - Hypercholesterolaemia;monocyte chemoattractant protein-1
UR - http://www.scopus.com/inward/record.url?scp=84860493918&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84860493918&partnerID=8YFLogxK
U2 - 10.1177/147323001204000246
DO - 10.1177/147323001204000246
M3 - Article
C2 - 22613445
AN - SCOPUS:84860493918
SN - 0300-0605
VL - 40
SP - 798
EP - 803
JO - Journal of International Medical Research
JF - Journal of International Medical Research
IS - 2
ER -
